{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:25:17Z","timestamp":1783952717419,"version":"3.55.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0237509","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T18:11:28Z","timestamp":1597774288000},"page":"e0237509","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-8778","authenticated-orcid":true,"given":"Saaya","family":"Tsutsu\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"pone.0237509.ref001","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"J Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"pone.0237509.ref002","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"D Chihara","year":"2014","journal-title":"Br J Haematol"},{"key":"pone.0237509.ref003","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.2015.1023712","article-title":"New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy","volume":"15","author":"D Chihara","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"pone.0237509.ref004","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ijc.29477","article-title":"Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006","volume":"137","author":"D Chihara","year":"2015","journal-title":"Int J Cancer"},{"key":"pone.0237509.ref005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12185-009-0475-2","article-title":"Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group","volume":"91","author":"R Seki","year":"2010","journal-title":"Int J Hematol"},{"key":"pone.0237509.ref006","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"B Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"pone.0237509.ref007","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"W Hiddemann","year":"2005","journal-title":"Blood"},{"key":"pone.0237509.ref008","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/1471-2407-14-586","article-title":"Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","volume":"14","author":"S Khor","year":"2014","journal-title":"BMC Cancer"},{"key":"pone.0237509.ref009","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis","volume":"19","author":"PA Hamlin","year":"2014","journal-title":"Oncologist"},{"key":"pone.0237509.ref010","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2018-0267","article-title":"Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA","volume":"14","author":"VA Morrison","year":"2018","journal-title":"Future Oncol"},{"key":"pone.0237509.ref011","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direst costs associated with replapsed diffuse large B-Cell lymphoma therapies","volume":"24","author":"A Purdum","year":"2019","journal-title":"Oncologist"},{"key":"pone.0237509.ref012","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","article-title":"Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas","volume":"22","author":"E Weidmann","year":"2011","journal-title":"Ann Oncol"},{"key":"pone.0237509.ref013","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/17474086.2017.1305264","article-title":"Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives","volume":"10","author":"A Chiappella","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"pone.0237509.ref014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2169\/internalmedicine.1587-18","article-title":"Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy","volume":"58","author":"M Hayashi","year":"2019","journal-title":"Intern Med"},{"key":"pone.0237509.ref015","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"DL Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"pone.0237509.ref016","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2217\/fon-2019-0019","article-title":"Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age","volume":"15","author":"PJ Lugtenburg","year":"2019","journal-title":"Future Oncology"},{"key":"pone.0237509.ref017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdq609","article-title":"Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper","volume":"22","author":"M Aapro","year":"2011","journal-title":"Ann Oncol"},{"key":"pone.0237509.ref018","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).","volume":"37","author":"JL Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0237509.ref019","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"SH Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"pone.0237509.ref020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000492942","article-title":"Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen","volume":"63","author":"M D\u0142ugosz-Danecka","year":"2018","journal-title":"Chemotherapy"},{"key":"pone.0237509.ref021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1524-4733.2007.00227.x","article-title":"Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center","volume":"11","author":"RC Lee","year":"2008","journal-title":"Value Health"},{"key":"pone.0237509.ref022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3747\/co.26.4565","article-title":"Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia","volume":"26","author":"S Costa","year":"2019","journal-title":"Curr Oncol"},{"key":"pone.0237509.ref023","first-page":"1","article-title":"Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database","author":"J Shaw","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"pone.0237509.ref024","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/annonc\/mdy203","article-title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials","volume":"29","author":"MJ Maurer","year":"2018","journal-title":"Ann Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T18:11:43Z","timestamp":1597774303000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237509"}},"subtitle":[],"editor":[{"given":"Gary D.","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0237509","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}